

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1-21. (Canceled)

22. (Withdrawn) A method for producing denatured lipoprotein, comprising:
freezing a solution containing lipoprotein to produce a frozen solution; and
melting the frozen solution to produce a solution containing denatured
lipoprotein.

23. (Withdrawn) The method according to claim 22, wherein said denatured
lipoprotein reacts with a DLH3 antibody which is yielded by hybridoma cell line, mouse-
mouse hybridoma FOH1a/DLD3 (Deposit No. FERM BP-7171).

24. (Withdrawn) The method according to claim 22, wherein the lipoprotein is at
least one selected from the group consisting of chylomicron, VLDL, LDL, Lp(a), HDL2
and HDL3.

25. (Withdrawn) A denatured lipoprotein produced by the method according to
claim 22.

26. (Withdrawn) The denatured lipoprotein according to claim 25, wherein said
denatured lipoprotein reacts with a DLH3 antibody which is yielded by hybridoma cell
line, mouse-mouse hybridoma FOH1a/DLD3 (Deposit No. FERM BP-7171).

27. (Previously Presented) A method for producing a stabilized denatured lipoprotein standard, comprising:

- freezing a first solution containing lipoprotein to produce a frozen solution of lipoprotein;
- melting the frozen solution to produce a melted solution of denatured lipoprotein;
- mixing a stabilizing agent with the melted solution to produce a second solution;
- and
- freeze-drying the second solution to produce a powder containing stabilized denatured lipoprotein.

28. (Canceled)

29. (Previously Presented) The method according to claim 27, wherein the lipoprotein is at least one selected from the group consisting of chylomicron, VLDL, LDL, Lp(a), HDL2 and HDL3.

30. (Withdrawn) A stabilized denatured lipoprotein produced by the method according to claim 27.

31. (Withdrawn) The stabilized denatured lipoprotein according to claim 30, wherein said stabilized denatured lipoprotein reacts with a DLH3 antibody which is yielded by hybridoma cell line, mouse-mouse hybridoma FOH1a/DLD3 (Deposit No. FERM BP-7171).

32. (Withdrawn) A method for producing stabilized denatured lipoprotein, comprising:

freezing a solution containing lipoprotein to produce a frozen solution;
melting the frozen solution to produce a solution containing denatured lipoprotein;
adding a stabilizer to the solution; and
freeze-drying the solution.

33. (Withdrawn) The method according to claim 32, wherein said denatured lipoprotein reacts with a DLH3 antibody which is yielded by hybridoma cell line, mouse-mouse hybridoma FOH1a/DLD3 (Deposit No. FERM BP-7171).

34. (Withdrawn) The method according to claim 32, wherein the lipoprotein is at least one selected from the group consisting of chylomicron, VLDL, LDL, Lp(a), HDL2 and HDL3.

35. (Withdrawn) A stabilized denatured lipoprotein produced by the method according to claim 32.

36. (Withdrawn) The stabilized denatured lipoprotein according to claim 35, wherein said denatured lipoprotein reacts with a DLH3 antibody which is yielded by hybridoma cell line, mouse-mouse hybridoma FOH1a/DLD3 (Deposit No. FERM BP-7171).

37. (Withdrawn) A method for determining denatured lipoprotein in a sample, comprising:

selecting the denatured lipoprotein according to claim 25;
reacting the sample with an antibody which binds to the denatured lipoprotein;
measuring the reactivity of the antibody with the sample; and
comparing the reactivity with a calibration curve previously formed from the denatured lipoprotein.

38. (Withdrawn) The method according to claim 37, wherein said determination is immunological determination.

39. (Withdrawn) The method according to claim 38, wherein said immunological determination is selected from among radio immunoassay, enzyme immunoassay, fluoroimmunoassay, luminescent immunoassay, agglutination immunoassay, immunonephelometry, and nephelometric immunoassay.

40. (Withdrawn) The method according to claim 39, wherein said method for immunological determination is a competitive method or a sandwich method.

41. (Withdrawn) The method according to claim 37, wherein said denatured lipoprotein is a standard substance for determining denatured lipoprotein in blood or an experimental reagent for investigating the physiological role or the physiological activity of denatured lipoprotein.

42. (Withdrawn) A method for determining denatured lipoprotein in a sample, comprising:

selecting the stabilized denatured lipoprotein according to claim 30;
reacting the sample with an antibody which binds to the denatured lipoprotein;
measuring the reactivity of the antibody with the sample; and
comparing the reactivity with a calibration curve previously formed from the denatured lipoprotein.

43. (Withdrawn) The method according to claim 42, wherein said determination is immunological determination.

44. (Withdrawn) The method according to claim 43, wherein said immunological determination is selected from among radio immunoassay, enzyme immunoassay, fluoroimmunoassay, luminescent immunoassay, agglutination immunoassay, immunonephelometry, and nephelometric immunoassay.

45. (Withdrawn) The method according to claim 44, wherein said method for immunological determination is a competitive method or a sandwich method.

46. (Withdrawn) The method according to claim 42, wherein said denatured lipoprotein is a standard substance for determining denatured lipoprotein in blood or an experimental reagent for investigating the physiological role or the physiological activity of denatured lipoprotein.

47. (Withdrawn) A method for determining denatured lipoprotein in a sample, comprising:

selecting the stabilized denatured lipoprotein according to claim 35;
reacting the sample with an antibody which binds to the denatured lipoprotein;
measuring the reactivity of the antibody with the sample; and
comparing the reactivity with a calibration curve previously formed from the denatured lipoprotein.

48. (Withdrawn) The method according to claim 47, wherein said determination is immunological determination.

49. (Withdrawn) The method according to claim 48, wherein said immunological determination is selected from among radio immunoassay, enzyme immunoassay, fluoroimmunoassay, luminescent immunoassay, agglutination immunoassay, immunonephelometry, and nephelometric immunoassay.

50. (Withdrawn) The method according to claim 49, wherein said method for immunological determination is a competitive method or a sandwich method.

51. (Withdrawn) The method according to claim 47, wherein said denatured lipoprotein is a standard substance for determining denatured lipoprotein in blood or an experimental reagent for investigating the physiological role or the physiological activity of denatured lipoprotein.

52. (Withdrawn) A reagent kit for determining denatured lipoprotein, comprising the denatured lipoprotein according to claim 25 as a standard substance.

53. (Withdrawn) A reagent kit for determining denatured lipoprotein, comprising the stabilized denatured lipoprotein according to claim 30 as a standard substance.

54. (Withdrawn) A reagent kit for determining denatured lipoprotein, comprising the stabilized denatured lipoprotein according to claim 35 as a standard substance.

55. (Withdrawn) A reagent kit for determining denatured lipoprotein, comprising a diluting liquid for a sample, a solid phase formed by immobilizing an antibody, a reaction buffer, a washing solution, a labeled secondary antibody, a detecting reagent, and the whole or part of the denatured lipoprotein set forth in claim 25 as a standard substance as component elements.

56. (Withdrawn) A reagent kit for determining denatured lipoprotein, comprising a diluting liquid for a sample, a solid phase formed by immobilizing an antibody, a reaction buffer, a washing solution, a labeled secondary antibody, a detecting reagent, and the whole or part of the stabilized denatured lipoprotein set forth in claim 30 as a standard substance as component elements.

57. (Withdrawn) A reagent kit for determining denatured lipoprotein, comprising a diluting liquid for a sample, a solid phase formed by immobilizing an antibody, a reaction buffer, a washing solution, a labeled secondary antibody, a detecting reagent, and the whole or part of the stabilized denatured lipoprotein set forth in claim 35 as a standard substance as component elements.

58. (Cancelled)

59. (Previously Presented) The method according to claim 27, further comprising, preceding the freezing step, adding an anti-coagulant to the solution containing lipoprotein.

60- 61. (Canceled)

62. (Previously Presented) The method according to claim 59, wherein the solution containing lipoprotein is plasma.

63. (Previously Presented) The method according to claim 27, wherein the solution containing lipoprotein is serum.

64. (Previously Presented) The method according to claim 27, wherein the solution containing lipoprotein is anticoagulant-containing plasma.

65. (Cancelled)

66. (Previously Presented) A method for producing a stabilized denatured lipoprotein standard, consisting essential of:

freezing a first solution containing lipoprotein to produce a frozen solution of lipoprotein;

melting the frozen solution to produce a melted solution of denatured lipoprotein;

mixing a stabilizing agent with the melted solution to produce a second solution;

and

freeze-drying the second solution to produce stabilized denatured lipoprotein in powder form.

Applicant(s) : Takashi Shigematsu et al.,
Serial No. : 10/009,151
Filed : April 16, 2002
Page : 15 of 20

Attorney Docket No.: 56501-002001
Client Ref. No.: F 2000-38-PCT/US

67. (Currently Amended) A method for producing a stabilized denatured oxidized lipoprotein standard, comprising:

freezing a first solution containing lipoprotein to produce a frozen solution of lipoprotein;

melting the frozen solution to produce a melted solution of denatured lipoprotein;

mixing a stabilizing agent with the melted solution to produce a second solution;

and

freeze-drying the second solution to produce a powder containing stabilized denatured oxidized lipoprotein that binds to antibody DLH3; and

~~determining an amount of the denatured lipoprotein in the powder~~

wherein the stabilized denature lipoprotein binds to a DLH3 antibody produced by hybridoma cell line FOH1a/DLH3 (Deposit No. FERM BP-7171).